Health Care • Biotechnology: Pharmaceutical Preparations
$40.15 ▲ +0.32
(+0.80%)
MKT CAP: $1.30B • VOL: 400.7K
52W L $14 52W H $50
ROARABLE / RQD
D- • 41/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$34
MEDIAN
$45
MEAN
$46
HIGH
$55
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LBRX TAPE
LBRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $48.58 | $46.17 | 2025-02-14 | $36.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $50.59 | $47.38 | 2025-02-06 | $37.74 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $45.77 | $44.16 | 2025-01-29 | $38.54 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $40.95 | — | 2025-01-17 | $39.35 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $35.33 | $38.14 | 2025-01-09 | $35.73 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $47.78 | $41.76 | 2024-12-18 | $34.93 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $38.95 | $40.55 | 2024-12-04 | $37.34 | -4.3% | 48% | C |